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ABSTRACT

Summary Background
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 is the most
comprehensive study ever carried out to report on the state of global public health for the
previous 28 years (1990-2017). In 2017, it covered 359 diseases and injuries for 195
countries and territories.

Our study sought to provide an up-to-date analysis of the progress that has been made to
eradicate diarrheal diseases using the GBD2017 data. Although significant progress has
been made in reducing the number of deaths due to diarrhea, diarrheal diseases
incidences and associated morbidity have not experienced the same level of decline.
Using disability-adjusted life-years (DALYs), a metric that tracks impact on life expectancy,
prevalence, and impact on quality of life due to a specific disease, we performed a
comparative analysis of the impact of diarrheal diseases by World-Bank (WB) Income
regions, age, and sex.

Methods
Using multi-year GBD data that we accessed from the Institute of Health Metrics (IHME)
tool (GBD Compare | Viz Hub), we analyzed the impact of diarrheal diseases using
Microsoft Office Excel 2017 (Microsoft, Redmond, WA). We compared the disability-
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adjusted life-year (DALY) metric due to diarrheal diseases among different demographic
subsets including sex, age, country, and income level. One DALY is comparable to one
lost year of “healthy” life, while the sum of DALYs across the population expresses the
burden of disease caused by a gap between current health status and optimal health for
the entire population impacting variables such as advanced age. All data estimates in the
GDB2017 study were listed with 95% uncertainty intervals (UIs).

We also evaluated DALYs as a function of the socio-demographic index (SDI). This index,
also developed by the GBD Project in 2015, is a measure of a region’s socio-demographic
development and consists of data about the education levels, average income per person,
and total fertility rate (TFR).

Findings
Diarrheal DALYs have decreased by approximately 54.64% from 1990 to 2017. In 1990
diarrheal

diseases

counts

were

estimated

at

178,669,278.768251

(95%

UI:

154,235,572.289659-203,868,117.467447) with an age-standardized DALY rate of
1,017.22180392645 per 100,000 people. On the other hand, in 2017, DALYs were
estimated at 81,039,363.8553969 (95% UI: 70,120,051.7904495 - 972,33,423.453799);
and an age-standardized DALY rate of 246 per 100,000 population globally. Interestingly,
while DALYs have decreased, incidence and prevalence have increased by 52.16% and
47.22%, respectively. Age-standardization, otherwise known as age adjustment, makes it

iii

possible to apply observed age-specific data from multiple populations to a standard age
distribution that enables comparison across countries and regions.

Regardless of World Bank (WB) Income region, infants 28-364 days were the most
vulnerable to diarrheal diseases. Since 1990, global diarrheal disease DALYs do not differ
markedly between the sexes. In 2017, there seems to be a slight difference in WB Highincome regions, where women have higher DALY rates (3.36% more), the rates in WB
Low-income regions were higher for males in 2017 (24.23%). We also observed that the
rate of diarrheal diseases highly correlates to socio-demographic index (R² = 0.9937).

Interpretation
Considerable progress has been made globally in reducing the burden of diarrheal
diseases, as many socio-economic risk factors have been reduced. However, progress
has not been up to par in all locations, Low-income countries are still substantially behind
in reducing diarrheal diseases DALY rates compared to High-income countries and the
burden of diseases infants still requires special attention.
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CHAPTER ONE
LITERATURE REVIEW

I.

Introduction

Diarrheal diseases are a long-standing and leading cause of avoidable death. According
to The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), in 2016,
diarrhea diseases ranked 8th among leading causes of death for all ages with 1,655,944
deaths (95% uncertainty interval [UI] 1,244,073–2,366,552). This number has decreased
by about 40% since 1990 (1). This is an astonishing lack of progress given that the risk
factors of diarrheal diseases, such as consumption of contaminated food and water, can
be easily avoided.

Children under two years of age are the most vulnerable to diarrheal diseases. This is
alarming because early crucial cognitive development takes place before the age of
18 months. Children who experience multiple bouts of diarrheal disease start at an
unequal footing for a quality life later in life, and experience less economic growth as adults
(2). Multiple studies have also shown that there is a correlation between the burden of
diarrheal disease and lower scores on the Test of Non-Verbal Intelligence-III and the
Wechsler Intelligence Scale for Children, impairment of visual-motor coordination, and
impaired auditory short-term memory and information processing in children who
experienced multiple episodes of diarrheal as infants, and risk of diabetes, malnutrition,
and cardiovascular disease (3-9). Further, diarrheal diseases have been linked to growth
stunting in children. An analysis of nine separate studies, done over a 20-year time period
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and in five countries, showed that stunting was directly linked to multiple episodes of
diarrhea in infants under two years of age, where five or more episodes of diarrheal before
24 months increased the probability of stunting by 25% (95% CI 8-38%). The same study
also showed that the likelihood of stunting was increased by 18% (95% CI 1-31%) for
children who suffered from diarrheal diseases at least 2% of the time before 24 months of
life (10).

The History of Diarrheal Diseases and Current Burden
The earliest recorded mention of diarrhea was in 460-370 B.C, where it was
described by Hippocrates as “an abundant liquid stool at short intervals (11).” In the 17th
century, diarrhea was classified into three categories by Jean Fernel according to
severity: bilious diarrhea in which the yellow bile moves out freely, severe diarrhea caused
by spleen dysfunction, and dysentery described as a bloody infection of the stomach with
pains and ulcers. At the time, it was believed that diarrhea was caused by poor hygiene
(12). By the 18th century, it was commonly understood that diarrhea was caused by poor
environmental and individual hygiene; however, the mechanism of infection was still
unclear (13). The first scientifically extensive study on diarrheal diseases was carried out
from 1960 to 1965 in seven different developing countries. The data showed that there
was a 40% prevalence of diarrheal diseases in children under six (14).

Diarrheal diseases still pose a major public health threat in developing countries. Every
year, since 1990, diarrheal diseases have been consistently ranked in the top ten causes
of morbidity and mortality for all age groups, while remaining in the top five causes of
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morbidity and mortality for children under 5. Even though prevention and treatment
strategies are known, it was the second leading cause of death among children under five
years old, killing 525,000 in 2017. According to The World Health Organization (WHO)
(15), in 2017, approximately 88% of individuals who died from diarrheal diseases were
infected by drinking unsafe water or living in a region with inadequate sanitation and
insufficient hygiene. Worldwide, 780 million individuals lack access to clean drinking-water
and 2.5 billion have no appropriate sanitation (15).

Categorization of Diarrheal Diseases Causative Agents
Today, it is well known that diarrheal diseases are caused by a variety of bacterial, viral
and parasitic organisms, and are propagated through the oral-fecal route. A list of
communicable diarrheal diseases and their causative agents are shown In Table 1. In this
review, we will explore the most common diarrheal diseases in each causative agent
category, their clinical symptoms, pathogenesis and virulence, and current control
strategies.
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Table 1: Diarrheal Diseases Causative Agents.

Causative Agent

Disease

Reviewed in

Vibrio cholerae

Cholera

Ref (16)

Salmonella typhii

Typhoid

Refs (17,18)

Salmonella enteritidis

Salmonellosis

Ref (19)

Listeria

Listeriosis

Ref (20)

Clostridium perfigens

C. perfringens food poisoning

Ref (21)

Clostridium difficile

C. difficile food poisoning

Ref (21,22)

Bacillus cereus

Diarrhoeal syndrome

Ref (23)

Escherichia coli

EPEC

Ref (24)

Escherichia coli

EHEC

Refs (24-26)

Shigella sonnei, Shigella boydii, Shigella

Shigellosis

Refs (27,28)

Campylobacter

Campylobacter infection

Refs (29,30)

Aeromonas

Traveler’s diarrhea

Ref (31)

Rotavirus

Rotavirus

Refs (32-36)

Norovirus

Norovirus

Ref (37)

Cytomegalovirus

Cytomegalovirus

Ref (38)

Cryptosporidiosis

Ref (39)

Giardia lamblia

Giardiasis

Refs (40,41)

Cyclospora cayetanensis

Cyclosporiasis

Ref (40)

Isospora belli

Cystoisosporiasis

Ref (41)

Blastocystis hominis

Blastocystis hominis infection

Ref (42)

Strongyloides stercoralis

Strongyloidiasis

Ref (43)

Microsporidium

Microsporidiosis

Ref (44)

Bacterial

dysenteriae and Shigella flexneri

Viral

Parasitic
Cryptosporidium parvum and Cryptosporidium
hominis

II.

Bacterial

Cholera

I.

Clinical Features

Cholera is caused by Vibrio cholerae. It is an aquatic bacterium that replicates on the
chitinous surface of copepods. V. cholerae strains are classified as serogroups based on
their surface antigens. In humans, only two V. cholerae, serogroups O1 and O139, are
known to cause disease. Serogroup O1 was discovered first and is the most common
cause (45).

The single most commonly recognized symptom of Cholera is the profuse watery diarrhea,
sometimes described as “rice-water stools.”. Other symptoms include vomiting, rapid
heart rate, loss of skin elasticity, dry mucous membranes, low blood pressure, thirst,
muscle cramps, restlessness, and/or irritability. In severe Cholera cases, illness can
progress into acute renal failure, severe electrolyte imbalances, and coma (45).

Despite being deadly within a few hours if left untreated, V. cholerae is fortunately
inefficient at infecting humans compared to other bacteria. A person must ingest more
than 500 V. cholerae bacteria to acquire a Cholera infection. Those who consume water
directly from copepod-contaminated water, however, are likely to get infected as each
copepod surface can carry up to 10,000 V. cholerae (45).

II.

Epidemiology

Cholera is prevalent in areas of high poverty. It is concentrated in Asia and Africa for the
most part, in countries that are ravaged by conflict, generally lack good infrastructure, have
inadequate health systems, and are plagued by malnutrition (45). According to the WHO,
there are between 1.3 and 4.0 million estimated cases of Cholera every year. Of those,
about 21,000 to 143,000 result in death (45). Due to fear of alienation in tourism and
trading, countries in endemic regions often underreport the number of Cholera cases. As
an example, only 1,227,391 cases were reported to the WHO globally in 2017 despite a
much larger estimate of actual cases (46). Another cause of underestimation of the
number of Cholera cases is due to the difficulty of documentation. Of those who are
infected, only 10% develop severe symptoms presenting watery diarrhea, vomiting and
leg cramps (45). Those who are not severely infected generally do not consult a health
practitioner limiting the documentation of illness.

Cholera is seasonal in endemic regions but can turn into large outbreaks in humanitarian
crisis situations. Since V. cholerae grows on copepods, the number of Cholera cases
surges during copepod growth season, which cycles with the seasonal proliferation of
phytoplankton, the main food source of copepods. As copepods increase in numbers, they
provide a rich growth medium for V. cholerae in waterways, leading to small outbreaks as
people consume contaminated water and spread the disease in a cycle of poor sanitation
(45).

Occasionally, these small outbreaks grow into epidemics in times of crisis. Since 2010,
there have been over 12 serious Cholera outbreaks including in Nigeria, Haiti, Dominican
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Republic, Venezuela, Democratic Republic of Congo, Somalia, Sierra Leone, Cuba,
Ghana, Tanzania, Burundi, Algeria, Zimbabwe, and mostly recently, Yemen, where there
is an active outbreak since 2017. Yemen’s Cholera epidemic started as a result of war
and became the largest recorded epidemic in one year since 1949, with 1.2 million cases
between 2017 and 2018 alone (47).

III.

Pathogenesis and Virulence

Cholera is mainly transmitted through consumption of food and water that have been
contaminated by the feces of an infected person. Upon ingestion, most V. cholerae
bacteria are killed on their journey through the digestive system. The surviving bacteria
move to the small intestine where they secrete a toxin, known as Cholera toxin. The
Cholera toxin is a heat labile heterotrimeric G protein-inhibiting exotoxin that is released
by the bacteria into the surrounding milieu. It consists of an A subunit bound to five B
subunits (48).

The first step in the Cholera toxin mechanism is the binding of its B subunit to the
ganglioside, GM1, receptor on host eukaryotic cells while the A subunit penetrates the
plasma membrane of the cell. Upon entering the cell, the A subunit prevents GTPase
activity by ribosylating its G alpha subunit. This activates adenylate cyclase, which in turn
leads to the elevation of intracellular cAMP, which stimulates chloride secretion in the
apical chloride channels on the intestinal epithelium which leads to hypersecretion of
sodium. The second major virulence factor of V. cholerae is through the toxin-co-regulated
pilus, which serves as a surface receptor for CTXφ. CTXφ is a filamentous bacteriophage
that encodes the Cholera toxin. The pilus is encoded within a genomic island, vibrio
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pathogenicity island (VPI-1). Virulence evolves through sequential acquisition of CTXφ
and VPI-1 and culminates in a hypersecretion of fluids. The hypersecretion of fluids then
leads to the signature high-volume “rice water” diarrhea that is usually associated with
Cholera (49,50).

IV.

Control and Therapies

The control of Cholera relies on four main strategies; prevention, monitoring and response
in outbreak crises, treatment, and vaccination. For prevention, the most basic and most
effective approach is improved sanitation. Better water and sewer infrastructure and water
safety would limit contamination and Cholera transmission. One of the cheaper methods
that have been used to prevent transmission is to filter copepods carrying V. cholerae out
of water using saris in Bangladesh. Studies carried out in Bangladesh showed a 48%
reduction in the transmission of Cholera using this method to filter drinking water (51).

Outbreak monitoring is important in endemic regions of Africa and Asia especially during
copepod season by testing water sources, primarily for phytoplankton blooms or increased
levels of V. cholerae. In non-endemic countries monitoring is also done after major natural
or man-made disasters where sanitation infrastructure has been destroyed. Patient
monitoring is also done by culturing stools for the presence of the bacterium. In addition,
there are rapid diagnostic tests (RDT), the most common one being the dipstick, which,
when dipped into stools, can signal the presence of V. cholerae in as fast as 15 minutes
There have been false negative cases; however, the Crystal VC test (by Span
Diagnostics), for instance, has about a 90% sensitivity and only a specificity of about 70%
(52). Here, sensitivity determines the ability to correctly identify those with the disease
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(true positive rate), whereas the specificity is the rate at which the test correctly identifies
those without the disease (true negative rate).

Although V. cholerae is a bacterium, antibiotics are not enough to prevent death.
Antibiotics kill the bacteria and reduce the duration of symptoms but have no effect on the
already secreted Cholera toxin. For this reason, the most commonly recommended
treatment for Cholera infection is oral or IV rehydration. According to the WHO 80% of
people can be successfully treated with immediate oral rehydration therapy (15,52).

Vaccination against Cholera has been in use since the 1980s. In the beginning, an
inoculated killed vaccine was widely used. However, the short-lived protection
(approximately 6 months) made this vaccine expensive for the people that needed it the
most. In addition to cost, this vaccine caused an inflammatory reaction at the injection site
in patients. Since those who needed it the most could not afford it and those who could
afford it did not want it due to side-effects, it got recommended by doctors less and less
(16).

The Food and Administration (FDA) recently approved Vaxchora (lyophilized CVD 103HgR) for adults 18-64 years, old who are traveling to an endemic or epidemic area. The
effectiveness of this vaccine in persons living in endemic areas has not been established.
The efficiency of protection is 90% after 10 days of inoculation and drops to 80% at 3
months after inoculation. Overall, protection is estimated to last between 3-6 months (53).
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Currently, there are two WHO approved oral vaccines for the prevention of Cholera,
Dukoral and Shanchol (also called mORCVAC depending on where it is produced). Both
vaccines are approved in over 60 countries worldwide, but not available in the US. Dukoral
(SBL Vaccin, Sweden) was produced and approved in Sweden in 1991. It is an oral
vaccine that is administered in two doses over a period of 1-6 weeks. It consists of heatkilled V. cholerae organisms and recombinant Cholera toxin B subunit. The vaccine leads
to antibacterial and antitoxic immunity due to this combination (53). In addition to its
protection against Cholera, Dukoral has the added benefit of partial protection against
diarrhea caused by enterotoxigenic E. coli (ETEC). The protection is due to the presence
of the recombinant Cholera toxin B, which shares high homology with a toxin from ETEC.
Although highly effective at protecting against Cholera, 85-90% protection only lasts for 46 months. Another weakness of Dukoral is that it only protects against O1 serotype V.
cholerae. Because of the short duration of protection, Dukoral is mostly prescribed to
short-term travelers and not to people living in endemic areas.

Shanchol (Shantha Biotechnics, India) or mORCVAC (VaBiotech, Vietnam) were
approved in both India and Vietnam in March 2009. Shanchol received WHO
prequalification, certifying that it meets the WHO international quality standards, in
November 2011. Compared to Dukoral, both vaccines have protection against O139
serotype in addition to O1 serotype. They have also been shown to have a longer duration
of protection in children and are cheaper to produce. The downside compared to Dukoral
is that Shanchol and mORCVAC do not have protection against ETEC (16).
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Shigellosis
I.

Clinical Features

Shigellosis is caused by the bacteria of the genus Shigella. Typical symptoms include
severe diarrhea, dysentery, abdominal cramps, fever, and rectal pain in mild
cases. Stunted growth is a risk in children who have experienced multiple bouts of
Shigellosis. Dysentery can lead to 200-300 mL of serum protein loss into feces daily. The
loss of serum protein, in turn, leads to extreme reduction of nitrogen stores which provokes
malnutrition and growth stunting (54).

Shigella is often referred to as “Traveler’s diarrhea” as it is commonly seen among
travelers, deployed military personnel, and expatriates to Low-income countries.
Symptoms usually manifest within 24-48 hours of infection. It manifests as persistent
diarrhea that can last up to 14 days (55,56). About 10-15% of patients develop chronic
functional bowel disorders after acute episodes of Shigellosis. Unlike Cholera or ETEC
that present as copious watery diarrhea, Shigellosis dysenteric stool is small and contains
blood, mucus, and inflammatory cells which have been cited as causes for irritable bowel
syndrome (57). Shigella is more dangerous than other gut pathogens because it can
penetrate the lining of the intestine and cause severe inflammation of the intestine and
systemic complications, which can lead to death if left untreated (54). In some children,
Shigellosis can trigger seizures. In adults, it can lead to Reiter’s Syndrome, causing
inflammation of the eyes and joints resulting in reactive arthritis (58).
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II.

Epidemiology

Humans are the primary hosts of Shigella. Shigellosis is transmitted through the oral-fecal
route and is endemic in developing countries where there is inadequate sanitation. In
developed countries, rare outbreaks are caused by uncooked contaminated food or
contaminated water. In 2016, Shigella was the second leading cause of diarrhoeal
mortality in 2016 among all ages, globally. It was the cause of an estimated 212,438
deaths (95% UI 136,979–326,913) and made up about 13·2% (95% UI 9·2–17·4) of all
diarrhoeal deaths. About 30% of total Shigella deaths were children under 5 with 63,713
deaths (95% UI 41,191–93,611) (59). Repeated infection is common as there are multiple
serotypes of Shigella, but evidence suggests that immunity is developed with age (60,61).

III.

Pathogenesis and Virulence Factors

Shigella are Gram-negative bacteria transmitted in food or water contaminated with feces
from an infected person. These bacteria like Escherichia are in the family of
Enterobacteriaceae. Shigella species and their serotypes along with their typical
geographic location are listed in Table 2.
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Table 2: Shigella species and Serogroups. There are four different Shigella species with
more than 20 serotypes. Serogroups A, B, and C are genotypically very similar. Positive
β-D-galactosidase and ornithine decarboxylase biochemical reactions are used to
differentiate S. sonnei from the other three serogroups.

Shigella species

Serogroups

S. dysenteriae

serogroup

Geographic location

A,

consisting

B,

consisting

of

12 Epidemic outbreaks

serotypes

S. flexneri

serogroup

of

6 Developing world

serotypes

S. boydii

serogroup C,

consisting of

18 Limited foci in India

serotypes

S. sonnei

serogroup D, consisting of a single U.S. and other industrialized
serotype

countries
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Most of the current knowledge on mechanisms of Shigella pathogenesis is derived from
studies of S. flexneri. The infection takes place in multiple steps. Infection is initiated when
the bacteria enter the intestinal mucosa and proceed to penetrate the intestinal epithelium,
the natural physical barrier that is meant to protect the body from pathogens (60). To cross
the epithelial layer, S. flexneri triggers its own uptake by phagocytosis into microfold cells
(M cells) and is released on the other side of the epithelium by vesicles trafficking and
exocytosis (transcytosis) (62,63). M cells are specialized epithelial cells (EC), they
transport antigens from the gut lumen and deliver them to the mucosal lymphoid tissue to
initiate immune response (64). Once inside the intraepithelial layer, S. flexneri are
immediately attacked by host macrophages. Normally, the macrophages engulf foreign
particles to degrade them. However, S. flexneri quickly induces apoptosis of the
macrophages as soon as they are engulfed to guarantee their survival (65-67).

With the macrophage death, there is subsequent release of cytokines interleukin-1 (IL-1)
and IL-18 (68,69). Both cytokines play a central role in the regulation of immune and
inflammatory responses to infections, in this case S. flexneri invasion. IL-1 signaling
initiates intestinal inflammation, which is characteristic of Shigellosis, while IL-18 causes
an antibacterial response by triggering natural killer (NK) cells and inducing the secretion
of gamma interferon (IFN-γ) (68,70). IL-8 leads to an increased recruitment of
polymorphonuclear neutrophil leukocytes (PMNs) to the site of infection (71,72). However,
evidence suggests that S. flexneri secrete effector proteins that influence migration of
PMN by modifying the transcriptional response of infected EC (73,74). As the PMNs are
compromised so is the integrity of the epithelial lining, which enables S. flexneri to enter
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the EC without the assistance of M cells (75,76). Eventually as infection gets worse, and
more PMNs are recruited, the bacteria are killed, and the infection is cleared (77-79).

The severe tissue destruction caused by Shigella, namely macrophage death, destruction
of the epithelial layer, and the massive influx of PMNs results in an impaired absorption of
water, nutrients, and solutes, which cause watery diarrhea and the appearance of blood
and mucus in Shigellosis stools (80). Another mechanism by which Shigellosis associated
diarrhea is thought to occur is triggered by Shigella enterotoxin 1 (ShET1) and ShET2,
which are produced by several Shigella strains. Evidence has shown that these two
enterotoxins induce fluid secretion into the intestine, causing the watery phase of diarrhea
(81,82).

Another toxin produced by Shigella is Shiga toxin, which is produced only by serotype 1.
Shiga toxin is toxic to different cell types. It causes the formation of vascular lesions in the
colon, the kidney, and the central nervous system (83). More so than S. flexneri and other
serogroups, infections with S. dysenteriae serotype 1 is associated with a higher risk of
life-threatening complications due to the high toxicity of Shiga toxin (80,84).

IV.

Control and Therapies

Prevention of oral-fecal route transmission is the primary means of control of Shigellosis.
The prevention is achieved through endemic population education and improvement of
sanitation infrastructure. Like Cholera, antibiotics can be used to shorten the length of
Shigellosis, however, to reduce the length of the disease and prevent death, they must be
used in conjunction with oral rehydration therapy to replenish fluids. Antibiotic-sensitivity
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tests are used to identify if the bacteria are resistant to antibiotics before prescribing a
medication.

Generally, Shigella infection is diagnosed by testing patient stools for the bacteria. A stool
sample is collected from the patient and placed on a growth medium for the bacteria. The
bacteria are microscopically identified when there is growth.

Currently, there is no vaccine approved for Shigellosis in the US. No vaccine for
Shigellosis is widely available. In China, a recombinant, live, oral, bivalent vaccine,
produced by the Lanzhou Institute of Vaccines and Biological Products, is available for
adults. The vaccine has approximately 60% efficacy for both S. flexinari and S. sonnei
(28). The vaccine has never been evaluated or approved for use outside of China.

III.

Viral

Rotavirus
I.

Clinical Features

Worldwide, irrelevant of economic development, Rotavirus is the leading cause of
diarrheal infection in children under 5 (85). Rotavirus infection presents with several
symptoms including abdominal pain, watery diarrhea, vomiting, and approximately onethird of patients have a fever of >39⁰C.

According to different sources Rotavirus can lead to afebrile and febrile seizures and
reduced consciousness. In afebrile cases, a study of 128 children in Italy showed that
convulsions typically occur within four days of Rotavirus onset and last about 5 minutes
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each (86). Febrile seizure symptoms tend to occur earlier after Rotavirus onset and last
longer on average than afebrile cases (87,88). Rotavirus has also been shown to cause
acute necrotizing encephalopathy (ANE) and cerebellitis/cerebellopathy (34).

After ingestion, Rotavirus travels to the small intestine, where it penetrates the epithelial
cell lining. It then replicates in the cytoplasm causing cellular damage and fluid secretion,
which result in profuse, watery diarrhea. The appearance of symptoms generally occurs
suddenly, after an incubation period of 1-2 days. Diarrhea, vomiting, and fever can last
between 4-7 days, during which time very large numbers of virus particles are shed in the
feces (97). Rotavirus infection can be symptomatic or asymptomatic depending on the
host. The main factor is age, but immunocompromised patients are at further risk of
having the virus spread beyond the small intestine to other organs. If untreated, symptoms
of Rotavirus can quickly lead to severe dehydration, electrolyte imbalance, metabolic
acidosis, and death in extreme cases.

II.

Epidemiology

Rotavirus is caused by ingestion of fecally-contaminated food and water and spreads via
the fecal-oral route. Humans can serve as reservoirs for the virus. About 1010-1011 virus
particles can be shed in a single stool, and it takes less than 100 particles of Rotavirus to
cause infection. Shedding of virus in feces has been shown to persist for weeks after
symptoms have stopped. Because of its stability in the environment, it can also be
transmitted through contact with contaminated objects or surfaces (32,35,89). Outbreaks
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tend to quickly spread in institutional settings, such as daycares, schools, and hospitals
(90).

Globally, in 2016, Rotavirus infection was responsible for more than 258 million episodes
of diarrhea among children younger than 5 (95% UI, 193 million to 341 million). Of those
cases, 128,500 resulted in death (95% uncertainty interval [UI], 104,500-155,600).
Poverty, malnutrition, and low birth weight are some of the conditions that increase the
risk of Rotavirus hospitalization. Over 80%, 104,733 deaths (95% UI, 83,406-128,842), of
the total number of deaths occurred in Sub-Saharan Africa where there is limited access
to vaccination (90).

III.

Pathogenesis and Virulence Factors

Rotaviruses belong to the family Reoviridae. They derive their name from the Latin word
rota meaning ‘wheel’, due to their round, wheel-like appearance when observed by
electron microscopy. Structurally, Rotaviruses are made up of a genome composed of 11
segments of double-stranded RNA (dsRNA) surrounded by a nonenveloped, complex,
triple-layered capsid structure. The triple-capsid layer is composed of an inner core, an
intermediate capsid, and an outer capsid surrounded by short spikes. Each segment of
RNA codes either a single viral structural protein (VP1 to VP4, VP6, and VP7) or
nonstructural protein (NSP1 TO NSP4), expect for segment 11 which codes for two
nonstructural proteins (NSP5 and NSP6), in overlapping reading frames (91). The
rotavirion consists of an inner core of RNA segments and molecules of VP1 and VP3
surrounded by VP2 protein (92,93). The middle core contains VP6 protein surrounded by
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a layer VP4 protein spikes, that are embedded in a VP7 capsid. These two play an
important role in enabling penetration of the virus into the epithelial lining.

The Rotavirus genus is classified into serological groups (A to E). Groups A to C infect
humans, Group A causing most infections, and all the remaining groups infect animals
(36). Rotaviruses are further classified into genotypes according to specific cut-off points
in nucleotide sequence identities.

There are multiple mechanisms through which Rotavirus causes diarrhea including, villus
ischemia, maladsorption caused by destruction of enterocytes or interference with their
absorptive abilities, enterotoxin activity and triggering of intracellular fluid secretion by
NSP4, and activation of the enteric nervous and vascular systems that lead to indirect
secretion (94-96).

IV.

Control and Therapies

Like other diarrheal diseases, supportive rehydration therapy rather than medications is
the recommended treatment for Rotavirus. Vaccination against Rotavirus has been
available since 2006. Four Rotavirus vaccines are currently in use globally: the
monovalent Rotarix (RV1), developed by GlaxoSmithKline, in Rixensart, Belgium and the
pentavalent RotaTeq (RV5), developed by Merck in West Point, PA, USA. RV1 is made
up of a single strain of Rotavirus derived from a human isolate and attenuated through
multiple cell culture passages. RV5 contains five attenuated strains of Rotaviruses, four
produced via the bovine Rotavirus isolate (G genotype) and one human isolate (P
genotype).The other two newer, WHO-approved vaccines are Rotavac™ , which is a
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naturally occurring bovine-human reassortant neonatal G9P, also called 116E developed
by Bharat Biotech in New Delhi, India, and RotaSiil™ a bovine-human reassortant with
human G1, G2, G3 and G4 bovine UK G6P backbone also developed in India by Serum
Institute of India (15).

Although vaccination does not entirely protect from contracting Rotavirus, both vaccines
have successfully reduced global Rotavirus gastroenteritis with vaccine effectiveness
ranging from 57% to 85% for RV1 and from 45% to 90% for RV5, lower childhood mortality
countries coming up on the higher end of success (98).

IV.

Parasitic

Cryptosporidiosis
I.

Clinical Features

Cryptosporidium has many species; however, C. hominis and C. parvum are responsible
for causing more than 90% of human cases of Cryptosporidiosis (99,100). Other species
that are less commonly associated with human disease include C. meleagridis, C.
cuniculus, C. felis, and C. canis.

The severity of a Cryptosporidium infection can vary from an asymptomatic shedding of
oocysts to a severe and life-threatening disease. C. hominis patients typically have more
severe symptoms including diarrhea, nausea, vomiting, and malaise, as well as other nonintestinal symptoms such as joint pain, eye pain, recurrent headaches, and fatigue. On
the other hand, C. parvum-, C. meleagridis-, C. canis-, and C. felis-infected patients only
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have diarrhea as a symptom (101). Regardless, of the responsible species, in rare cases,
patients have other nonspecific symptoms such as myalgia, weakness, and anorexia as
a result of Cryptosporidiosis (102).

Several parasite characteristics and host factors influence the virulence, persistence, and
overall severity of the Cryptosporidiosis infection. Although not much is known about
parasite factors, studies have shown that immunocompromised individuals such as
HIV/AIDS patients, with T cell counts of <50, are at the greatest risk (103-109). Frequent
exposure is another host-defining factor for individuals who live in areas that lack adequate
sanitation (99).

When infected, otherwise healthy individuals (immunocompetent), can naturally eliminate
the infection in two to three weeks. For immunocompromised individuals, however, the
disease can evolve into a life-threatening condition causing dehydration and wasting (110112), atypical gastrointestinal disease, biliary tract disease, respiratory tract disease, and
pancreatitis, and in some cases leading to death (113-115).

II.

Epidemiology

Cryptosporidiosis is the leading waterborne disease from recreational waters in the United
States. Globally, Cryptosporidiosis was the fifth leading diarrheal disease in children
younger than 5 years with more than 48,000 documented deaths (95% UI 24,600–81,900)
and more than 4.2 million disability-adjusted life-years lost (95% UI 2·2 million–7·2 million)
in 2016 (116).
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The first cases of human Cryptosporidiosis were reported in 1976 (110,117).
Cryptosporidiosis was established as a global public health threat when it was recognized
as lethal to immunocompetent individuals (118,119). Its status as a significant waterborne
disease was cemented with large-scale outbreaks of human Cryptosporidiosis in the UK
(Swindon and Oxfordshire) and USA (Milwaukee, WI), where contaminated water was
identified as the cause (120,121).

Cryptosporidium can be transmitted both through direct and indirect routes. The most
common direct transmission is the fecal-oral route, where infected hosts shed
contaminated stools. From there, parasites are transferred from animal-to-animal, animalto-human (zoonotic), human-to-animal, or human-to-human (anthroponotic) (39,122,123).
Human-to-human transmissions are well documented in outbreaks in closed settings such
as daycare centers and hospitals (124). Zoonotic transmissions typically occur when
veterinary students and researchers are exposed while treating animals in outbreaks
where a strain that infects both humans and animals is involved. Indirect transmission
usually occurs when the susceptible host encounters water, food, or surfaces that have
been

fecally-contaminated

with

Cryptosporidium

(125,126).

In

rare

cases,

immunocompromised hosts and children can also get sick from inhaling oocysts from the
environment (127-129). This form of contamination leads to laryngotracheitis, a respiratory
disease, in addition to mild diarrhea.
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III.

Pathogenesis and Virulence

Cryptosporidium belong to the same phylum as other medically important parasites such
as Plasmodium and Toxoplasma, which are called apicomplexan parasites. Like other
diarrheal diseases, Cryptosporidiosis is transmitted through the oral-fecal route when a
susceptible host consumes contaminated food and water.

The established infective life cycle of Cryptosporidium begins when the host ingests
sporulated oocysts. The oocysts then undergo excystation and release four infectious
sporozoites. Temperature and pH alone can induce excystation, however, reducing
conditions, carbon dioxide, pancreatic enzymes, and bile salts have also been cited as
causes of oocysts excystation (103,130-132).

Like most apicomplexan parasites, Cryptosporidium sporozoites possess gliding motility
that enables them to move across the surface of the host cell (132). As sporozoites glide
across the surface of the small intestine, the rhoptries and micronemes, in the parasite’s
apical complex, release proteins that enable them to adhere to and invade the cell, and
thereafter induce the host cell membranes to enclose the parasites into a parasite modified
host membrane called the parasitophorous vacuole (PV) (133-137). Once inside the PV,
each sporozoite matures into a spherical trophozoite, that undergoes merogony to
asexually produce a type I meront containing eight merozoites (103). Each of the eight
merozoites attaches to a neighboring epithelial cell after being released and undergoes
merogony on its turn to produce either a second-generation type 1 meront or a type 2
meront (which only contains four merozoites).
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Figure A: Cryptosporidium Life Cycle. Sporulated oocysts, containing 4 sporozoites,
are excreted by the infected host through feces (and possibly other routes such as
respiratory secretions). Transmission of Cryptosporidium spp. occurs mainly through
ingestion of fecally contaminated water (e.g., drinking or recreational water) or food (e.g.,
raw milk) or following direct contact with infected animals or people
. Following
ingestion (and possibly inhalation) by a suitable host
, excystation occurs. The
sporozoites are released and parasitize the epithelial cells ( , ) of the gastrointestinal
tract (and possibly the respiratory tract). In these cells, usually within the brush border, the
parasites undergo asexual multiplication (schizogony or merogony) ( , , ) and then
sexual
multiplication
(gametogony)
producing
microgamonts
(male) and
macrogamonts (female) . Upon fertilization of the macrogamonts by the microgametes
( ) that rupture from the microgamont, oocysts develop and sporulate in the infected
host. Zygotes give rise to two different types of oocysts (thick-walled and thin walled).
Thick-walled oocysts are excreted from the host into the environment
, whereas thinwalled oocysts are involved in the internal autoinfective cycle and are not recovered from
stools . Oocysts are infectious upon excretion, thus enabling direct and immediate
fecal-oral transmission. Extracellular stages have been reported, but their relevance in the
overall life cycle is unclear (141). https://www.cdc.gov/dpdx/cryptosporidiosis/index.html

24

The type 2 merozoites are then released, but instead of undergoing merogony again, they
begin gametogony to produce either microgamonts (male) or macrogamonts(female)
(138,139).

The

molecular

mechanisms

governing

gametogamy

are

poorly

understood. Each microgamont goes through nuclear division and differentiates into 16
microgametes, while each macrogamont forms a unicellular macrogametocyte. Once
released from the PV, the microgametes locate the unucleated macrogametocytes to
fertilize them, forming zygotes. The zygote then goes through two asexual cycles of
sporogony producing an oocyst that either has a thick wall or a thin wall, containing four
sporozoites (140). Finally, the thick-walled infective oocysts are excreted from the host in
feces enabling the repetition of the infective life cycle of Cryptosporodium if consumed by
another susceptible host. Thin-walled oocysts remain inside the host and are involved in
the internal autoinfective cycle (139).

IV.

Control and Therapies

For the general public, the CDC recommends maintaining good sanitation by avoiding
food and water that might be contaminated, and properly washing hands (alcohol-based
hand sanitizers are not effective against the parasite) as a means of control of
Cryptosporidium. In day care facilities, it is recommended to isolate children with diarrhea
symptoms from groups to avoid small outbreaks (141).

Cryptosporidiosis symptoms disappear in healthy individuals within two to three weeks.
However, children and pregnant women are at a greater risk of dehydration. Rehydration
therapy is recommended in these cases. Where diarrhea symptoms are persistent,
Nitazoxanide, an FDA-approved drug, is recommended. For immunocompromised
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individuals, Nitazoxanide has not been documented as a cure for Cryptosporidiosis.
However, taking anti-retrovirals reduces susceptibility and vulnerability to diseases that
are AIDS- associated in HIV/AIDS patients by strengthening their immune system (141).
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ABSTRACT

Summary Background
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 is the most
comprehensive study ever carried out to report on the state of global public health for the
previous 28 years (1990-2017). In 2017, it covered 359 diseases and injuries for 195
countries and territories.

Our study sought to provide an up-to-date analysis of the progress that has been made to
eradicate diarrheal diseases using the GBD2017 data. Although significant progress has
been made in reducing the number of deaths due to diarrhea, diarrheal diseases
incidences and associated morbidity have not experienced the same level of decline.
Using disability-adjusted life-years (DALYs), a metric that tracks impact on life expectancy,
prevalence, and impact on quality of life due to a specific disease, we performed a
comparative analysis of the impact of diarrheal diseases by World-Bank (WB) Income
regions, age, and sex.

38

Methods
Using multi-year GBD data that we accessed from the Institute of Health Metrics (IHME)
tool (GBD Compare | Viz Hub), we analyzed the impact of diarrheal diseases using
Microsoft Office Excel 2017 (Microsoft, Redmond, WA). We compared the disabilityadjusted life-year (DALY) metric due to diarrheal diseases among different demographic
subsets including sex, age, country, and income level. One DALY is comparable to one
lost year of “healthy” life, while the sum of DALYs across the population expresses the
burden of disease caused by a gap between current health status and optimal health for
the entire population impacting variables such as advanced age. All data estimates in the
GDB2017 study were listed with 95% uncertainty intervals (UIs).

We also evaluated DALYs as a function of the socio-demographic index (SDI). This index,
also developed by the GBD Project in 2015, is a measure of a region’s socio-demographic
development and consists of data about the education levels, average income per person,
and total fertility rate (TFR).
Findings
Diarrheal DALYs have decreased by approximately 54.64% from 1990 to 2017. In 1990
diarrheal

diseases

counts

were

estimated

at

178,669,278.768251

(95%

UI:

154,235,572.289659-203,868,117.467447) with an age-standardized DALY rate of
1,017.22180392645 per 100,000 people. On the other hand, in 2017, DALYs were
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estimated at 81,039,363.8553969 (95% UI: 70,120,051.7904495 - 972,33,423.453799);
and an age-standardized DALY rate of 246 per 100,000 population globally. Interestingly,
while DALYs have decreased, incidence and prevalence have increased by 52.16% and
47.22%, respectively. Age-standardization, otherwise known as age adjustment, makes it
possible to apply observed age-specific data from multiple populations to a standard age
distribution that enables comparison across countries and regions.

Regardless of World Bank (WB) Income region, infants 28-364 days were the most
vulnerable to diarrheal diseases. Since 1990, global diarrheal disease DALYs do not differ
markedly between the sexes. In 2017, there seems to be a slight difference in WB Highincome regions, where women have higher DALY rates (3.36% more), the rates in WB
Low-income regions were higher for males in 2017 (24.23%). We also observed that the
rate of diarrheal diseases highly correlates to socio-demographic index (R² = 0.9937).
Interpretation
Considerable progress has been made globally in reducing the burden of diarrheal
diseases, as many socio-economic risk factors have been reduced. However, progress
has not been up to par in all locations, Low-income countries are still substantially behind
in reducing diarrheal diseases DALY rates compared to High-income countries and the
burden of diseases infants still requires special attention.
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I.

Introduction

Diarrheal diseases have long been distinguished as a serious global health problem,
particularly in developing countries. Acute diarrhea is normally caused by infection with
viral (e.g., Norovirus (1), Rotavirus (2)), bacterial (e.g., Campylobacter (3), Escherichia
coli (4), Salmonella (5), Shigella (6)), or parasitic (e.g., Entamoeba histolytica (7), Giardia
lamblia (8), Cryptosporidium enteritis (9)) etiological agents. On the other hand, chronic
diarrhea can have non-communicable derivations such as food allergies and intolerances,
celiac disease, Crohn’s disease, ulcerative colitis, or long-term use of medicines such as
antibiotics, antacids or other drugs.

According to World Health Organization (WHO) Global Health Observatory (GHO) data,
in 2016, diarrhea was the ninth leading cause of mortality globally, responsible for more
than 1.3 million total deaths (10). Many factors including age, environment, and sex can
exacerbate the impact of diarrhea for various demographic groups. For example, the
impact of diarrheal disease on children is substantial. In 2017, global data show that
diarrheal diseases rank third among all causes of mortality in children younger than five
(11). This demographic made up more than a quarter (33.38%) of global diarrheal deaths
altogether and multiple reports have explored reasons for this burden (1214). Furthermore, there is a growing body of evidence that shows that children, who suffer
from multiple bouts of diarrhea, especially before the age of two, experience poor physical
growth(15), poor cognitive development(16,17), and are at higher risk for the development
of type 2 diabetes, metabolic syndrome, obesity and related co-morbidities (18,19).
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Location is another critical factor that has bearing on the number of diarrheal diseases
deaths. Evidence has shown that Low-income regions, with poor access to health care,
safe water, and sanitation, and with higher numbers of marginalized populations are the
most vulnerable. For example, 87% of diarrheal deaths occurred in South Asia and subSaharan Africa in 2015(20).

Women made up more than half (52.23%) of all diarrheal deaths in 2017. Cultural factors
influence this disparity among sexes. For instance, in some sub-Saharan Countries,
especially in more unstable, violent settlements, many women have reverted to using
unclean forms of sanitation such as bucket toilets even when clean forms are
available. This may be the result of fear of physical and sexual violence that comes with
using public sanitation facilities (21,22). Other research suggests that women's sanitation
use may be affected by their fear of contracting infections from unclean sanitation facilities
(23,24).

Despite these statistics, if we consider mortality rates overall, global health has improved
tremendously as life-expectancy has almost doubled since the 1950s [6–7]. Much of this
progress has to do with the improvements made that have led to a reduction of child
mortality rates. For example, since 1990, mortality for children under five has declined by
57% and 68% for all causes and diarrheal causes, respectively (25,26). Despite this dropin diarrhea-related mortality, the incidence of diarrheal disease, in this same age group,
has experienced a less pronounced declivity (26), decreasing only by on 24% during the
same time period.
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Ageing populations further challenge the ability to limit diarrheal disease. According to UN
estimates, individuals older than 60 years of age will grow from 962.3 million in 2017 to
2080.5 million in 2050 (27). This growth will occur mainly in Africa, for which it is estimated
that individuals over the age of 60 will increase by 230% over this time period. In 2016,
diarrhea mortality was approximately three times higher in adults older than 70 years of
age than in children younger than 5 years (28).

An important framework for the eradication of diarrheal diseases is that they mostly occur
in Low-income countries. Low-income countries do not have suitable infrastructure and
enough resources that can be dedicated to this task (24). It is, therefore, important for
there to be a focus not only on measuring mortality rates, but also on lost healthy years.
A disability-adjusted life-years (DALY) is a metric that can track disease burden as it
incorporates both current and long-term burden and expresses morbidity as years of life
lost as a result of premature mortality as well as years lived with disability (29).

In this study, we examined the burden of diarrheal diseases from 1990 to 2017 based on
the data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
(GDB2017) (26). Specifically, we conducted a longitudinal analysis of DALYs associated
with diarrheal diseases by country, age, and sex.
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II.

Methods

Overview
The Global Burden of Disease (GBD) Project was initiated in 1990, to provide wideranging, global-level, assessments of data human health. A consortium of project
collaborators has tracked the mortality and morbidity associated with 359 diseases
(communicable and non-communicable) (30), with 3484 sequelae and 84 risk factors for
each of 195 countries and territories and the globe from 1990 to 2017. The data in the
GBD2017 are extracted from 68,781 data sources and are reported by region, age, and
sex, allowing for a variety of comparisons by time, sex, population and other demographic
groupings (28). The first data set (for the initial year 1990) was published in the World
Development Report 1993 (30). This international consortium is managed by the Institute
for Health Metrics and Evaluation (IHME; Seattle, WA).

Analysis of Data
Using multi-year GBD data, we analyzed the impact of diarrheal diseases using Microsoft
Office Excel 2019 (Microsoft, Redmond, WA). Specifically, we compared the disabilityadjusted life-year (DALY) metric due to diarrheal diseases among different demographic
subsets including sex, age, country, and income level.

The latter followed World Bank (WB) income categories: High income, Low income, Lower
middle income, Upper middle income. One DALY is comparable to one lost year of
“healthy” life, while the sum of DALYs across the population expresses the burden of

44

disease caused by a gap between current health status and optimal health for the entire
population impacting variables such as advanced age. Simply put, one DALY equals the
sum of the Years of Life Lost (YLL) due to premature mortality in the population and the
Years Lost due to Disability (YLD) for people living with the health condition or its
consequences. Further details on the methods used in data modeling for the GDB2017
can be found in other publications (31,32).

When comparing WB High-income regions to WB Low-income regions, and males to
female, we used age-standardized data, which is essentially age adjusted data, to enable
comparison across populations with varying age demographics.

We also evaluated DALYs as a function of the socio-demographic index (SDI). This index,
also developed by the GBD Project in 2015, is a measure of a region’s socio-demographic
development and is comprised of data about the education levels, average income per
person, and total fertility rate (TFR). The SDI is expressed on an interpretable scale of
zero to one, where zero represents the lowest educational achievement, lowest income
per capita, and highest TFR, and one represents the highest educational achievement,
highest income per capita, and lowest TFR. All data estimates in the GDB2017 study were
listed with 95% uncertainty intervals (UIs).
Data Visualization
To compare data, we used MS Excel 2016 to model and visualize data exported from
the IHME tool (GBD Compare | Viz Hub) (26).
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Ethics Statement
This study was based on secondary databases which are publicly available, without
identification of individual data.
III.

Results

Summary of Global DALYs due to Diarrheal Disease
To assess the global impact of diarrheal diseases, many previous studies have focused
on mortality statistics (32-35). However, given that global mortality rates are decreasing,
and given that individuals are living longer, it is imperative to also look at the burden of
diseases, including diarrheal diseases, from the perspective of disability. Therefore, we
examined yearly DALYs attributable to diarrheal diseases using GBD Project data. To the
best of our knowledge, this is the only longitudinal study of diarrheal diseases DALYs that
encompasses all 28 years of data available from the GBD. The GDB2017 categorizes
diseases, causes and their sequelae into four hierarchical levels (Figure1).
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Level 1

Communicable,
maternal and
neonatal
conditions and
nutritional
diseases (CMNN)

Level 2

Level 3

Level 4

21 diseases
and injuries

167 causes

288 causes

Noncommunicable
diseases (NCDs)

Injuries

Figure 1: GBD Hierarchical Levels: Level 1 consists of three broad cause groups:
communicable, maternal and neonatal conditions and nutritional diseases (CMNN); noncommunicable diseases (NCDs); and injuries. There are 21 diseases and injuries
categories at Level 2. Level 3 and Level 4 break down causes to the smallest level of detail
with 167 causes, and 288 causes, respectively. Diarrheal diseases are classified in level
3 causes under enteric infections.
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Appendix 1 summarizes the global estimates for DALYs, incidence, and prevalence for
diarrheal diseases from 1990 and 2017. Appendix 1 also includes the annual sociodemographic index as reported in the GBD2017 results.

In 1990 DALYs counts were

estimated at 178,669,278.77 (95% UI: 154,235,572.29 - 203,868,117.47) with an agestandardized DALY rate of 1,017.22 per 100,000 people. On the other hand, in 2017,
DALYs were estimated at 81,039,363.85 (95% UI:70,120,051.79 - 972,33,423.45); and an
age-standardized DALY rate of 246.01 per 100,000 population globally. Thus, diarrheal
DALYs have decreased by approximately 54.64% since 1990.

Interestingly, while DALYs have decreased, incidence and prevalence have increased by
52.16% and 47.22%, respectively (Appendix 1). Specifically, diarrheal disease incidence
was estimated at 4,135,836,824.13 (95% UI: 3,811,339,413.89 - 4,500,759,366.83) in
1990, compared to 6,292,936,671.74 (95% UI: 5,808,374,688.14 - 6,816,675,433.15) in
2017. Diarrheal disease prevalence was estimated at 63,492,658.0347 (95% UI
59,217,728.40 – 68,111,097.50) in 1990, compared to 93472768.36 (95% UI:
86857153.63 - 99961050.16) in 2017. Overall, these data suggest that treatments may
have improved, which has led to a lower number of lost healthy years due to diarrheal
disease; however, there may be a lack of progress in prevention methods.

SDI is a summary measure of where countries or other geographic areas are on the
spectrum of development. The SDI measure is expressed on a scale of 0 to 1 and
incorporates three different aspects of development: income per capita, education, and
fertility. A zero SDI value indicates a Low-income region, while an SDI value of one
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indicates a High-income country. The global SDI value increased from 0.52 in 1990 to
0.65 in 2017 indicating that there has been global economic progress overall. The increase
in SDI may be an indicator of enhanced access to health care, and specifically enhanced
availability of treatments for diarrheal diseases, leading to the decrease in associated
DALYs.

Global Diarrheal Disease DALYs Differ by World Bank (WB) Economic Region
Economic stability is another important factor that affects the number of DALYs in each
region. Although global DALYs, due to diarrheal disease, decreased from 1990 to 2017, it
is important to understand if different WB economic regions vary in their progress toward
treatment and eradication of diarrheal diseases. Therefore, we compared diarrheal
diseases DALYs per 100,000 people in WB Low-income regions to that of WB Highincome regions from 1990 to 2017.

In 1990, DALYs per 100,000 were highest in Niger with an estimate of 17,633.63 (95%
UI: 12,873.65 - 22,679.68) and lowest in North Korea with an estimate of
370.910371233981 (95% UI: 705.48 - 238.14) (Figure 2). In 2017, the DALYs per 100,000
were highest in Central African Republic with an estimate of 8,590.04 (95% UI: 5,449.51
- 12,230.82) and, once again, lowest in North Korea with an estimate of
381.568756222037 (95% UI: 270.49 - 808.57) (Figure 2).
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Figure 2: World Bank Low-income DALYs per 100,000 Age-standardized for Both
Sexes (1990-2017).
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In 1990, in the WB High-income regions (Figure 3), Saudi Arabia exhibited the highest
DALYs per 100,000 with an estimate of 962.35 (95% UI 1374.01- 662.02), and the
Netherlands had the lowest DALYs per 100,000 with an estimate of 16.52 (95% UI: 21.60
- 12.27). In 2017, Guam had the highest DALYs per 100,000 with an estimate of 483.37
(95% UI: 663.90 - 335.04) while Malta had the lowest DALYs per 100,000 with an estimate
of 25.90 (95% UI: 33.28 - 19.58).

We also compared the highest DALYs per 100,000 in both economic regions. Not
surprisingly, there were substantially more DALYs per 100,000 in WB Low-income regions
than in High-income regions with a ratio of 697:1. However, there was an interesting
temporal trend observed. In the case of WB Low-income regions, there was a steady
decline in DALYs per 100,000 with an overall decrease of 58% from 1990-2017 (Figure
2). On the other hand, in the case of WB High-income regions, there was a decline of
DALYs per 100,000 from 1990 to 1998, after which there was an increase almost every
year up to 2017 (Figure 3). Thus, the cumulative decrease, from 1990 to 2017, in DALYs
per 100,000 of 2% in WB High-income regions is markedly lower than that of WB Lowincome regions. An annual increase in diarrheal disease DALYs per 100,000 in Bahrain,
Bermuda, Demark, Germany, and the US Territories of Guam, the Northern Mariana
Islands and Puerto Rico as well as the little change in Antigua and Barbuda, Chile,
Barbados, Estonia, Trinidad and Tobago, may have contributed to this apparent lack of
progress in WB High-income regions.
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Figure 3: World Bank High-income DALYs per 100,000 Age-standardized—Both
Sexes (1990-2017).
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Global Diarrheal Diseases DALYs Do Not Differ Markedly Between the Sexes in 2017
Previous data suggest that diarrheal diseases disproportionately affect boys compared to
girls (32). The specific reasons for this uneven distribution among the sexes are still
unclear. One hypothesis state that boys younger than five years old are more likely to be
exposed to infectious pathogens in Low-income countries due to social and cultural
reasons including their general ability to move and play outside the home more than girls
(31). To determine if the diarrheal diseases in males and females were differentially
contributing to the unusual temporal pattern of DALYs in WB High-income regions, we
compared age-standardized DALY rates per 100,000 by sex in both economic regions.

As shown in Figures 4 and 5, temporal patterns of DALYs for both males and females, in
WB High-income regions, separately, was similar to that for both sexes combined (Figure
3) in that there was an apparent decline in DALYs per 100,000 from 1990 to approximately
1998, after which there was an increase almost every year up to 2017. For both males
and females, Saudi Arabia reported the highest DALY rates per 100,000 in 1990 with
1869.28 (95% UI: 3073.62 - 1125.10) and 1093.24 (95% UI: 1785.80- 624.55),
respectively, in WB High-income regions. In 2017, Guam had the highest diarrheal
diseases DALY rates for both males and females at 474.16 (95% UI: 659.41 - 328.91) and
490.68 (95% UI: 674.91- 336.08), respectively.
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Figure 4: World Bank High-income DALYs per 100,000 Age-standardized—
Female (1990-2017).
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Figure 5: World Bank High-income DALYs per 100,000 Age-standardized—Male
(1990-2017).
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We also combined the data for the diarrheal diseases DALYs for males and females in
Figure 6. Females consistently had higher DALY rates per 100,000 both in 1990 and
2017 both in Saudi Arabia and in Guam, the two most affected countries in WB HighIncome countries. In 1990, in Saudi Arabia, the rate of diarrheal diseases in females was
41.5% higher than that in males. That gap was considerably smaller in Guam in 2017,
where there was a 3.36% difference in diarrheal diseases rates between females and
males. The lower rates of diarrheal diseases for both sexes in 2017 in the High-income
region are encouraging, however, work remains to be done to increase the speed at which
diarrheal diseases are eradicated.
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Figure 6: WB High-income Male and Female DALY Rates Combined 1990 vs. 2017.
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In Figures 7 and 8, we repeated the analysis by sex, but this time in the World Bank
Low-income regions. Niger had the highest diarrheal disease DALY rates for females
in 1990 at 40,880.10 (95% UI: 26,685.78 - 56,133.80), while Chad had the highest
DALY rates per 100,000 in 2017 at 11,109.24 (95% UI: 7,993.22 - 15,282.68). Chad
reported the highest DALY rates for males both in 1990 and 2017 at 27,230.37(95%
UI:17,459.49 - 40,318.61) and 14,662.02 (95% UI: 10,053.10- 20,477.33),
respectively.
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Figure 7: World Bank Low-income DALYs per 100,000 Age-standardized—
Female (1990-2017).
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Figure 9 summarizes these data for both sexes. Like WB High-income regions, Lowincome regions had disproportionate DALY rates per 100,000 for women in 1990, in
Niger, diarrheal diseases DALY rates were 38.39% higher in females than in males.
However, this dynamic changed in Chad in 2017, where males had 24.23% higher
rates of diarrheal disease than females. A hypothesis for this progress seen in women
in Low-income countries since 1990, can be attributed to their progress in other areas
such as education which has enabled them to be aware of preventable diseases such
as diarrheal diseases (36).

North Korea stands out in Figure 9, barely having any DALY rates reported. Reliable
estimates of the burden of diseases in North Korea are widely unavailable and the
WHO ranks available raw data at the lowest level of credibility.

Overall, these data suggest that the disproportionately higher number of diarrheal
diseases DALY rates observed for boys versus girls in children under five years old
does not remain true in age-standardized DALY rates. Since 1990, the gap between
males and females in both economic regions have been narrowed.
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Figure 9: Comparison of Diarrheal Disease Burden Between Sexes from 1990 to 2017
in WB Low-income.

Diarrheal Diseases DALYs Rates by Age in WB Low-income Countries and WB
High-income Countries
Up to this point, we based our analysis on age-standardized DALY rates comparing
WB High-income and WB Low-income. Previous data have shown that young children
under five are particularly vulnerable to diarrheal diseases (32). In many Low-income
countries, lack of sanitary facilities and hygienic practices, fly infestations, and regular
consumption of street food constitute some of the leading causes of diarrheal disease

(37-39).

In Figure 10, we compared different age categories’ vulnerability to diarrheal diseases
using DALYs by age category in WB Low-income regions. The 28-364 days age group
emerged as the most vulnerable demographic to diarrheal diseases by far with
13,949,996.98 DALYs (95% UI: 1,172,1297.30 – 1,622,0597.90) in 1990, and
8,170,515.87 DALYs (95% UI: 7,028,902.56 – 9,511,204.72) in 2017.

In Figure 11, we removed the first ten years of life to analyze how the remaining age
demographics fare. Two additional peaks emerged, one at ages 20-24 and the other
at 60-64 years. The Peak at 20-24 has not been explained in previous literature. Our
hypothesis is that the sudden spike in diarrheal DALY rates is contamination of young
mothers and fathers by their infants and toddlers. Previous studies have reported that
diarrhea impacts at least 9% of the elderly population at any given time. This has a
significant negative impact on their quality of life, increasing their hospital visits and
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hospitalization (51). Other studies have reported that diarrheal diseases in the elderly
population are a significant cause of fecal incontinence (52), morbidity (53,54), and
mortality (35). Long-term care facility stay for the elderly was cited as a risk factor for
diarrheal diseases (35). Consumption of multiple medications was also reported as a
risk factor for diarrheal disease, with a 11.0% increase of diarrheal disease prevalence
in patients who were taking 3–5 drugs, and an 11.7% increase in patients taking 6 or
more drugs at once (55) .
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Figure 11: Diarrheal Disease DALYs Counts by Age (1990-2017) in WB Low-income.
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In Figure 12, we repeated the same age group comparison in WB High-income
countries. Overall, in High-income countries, infants 28-364 days old, were the most
vulnerable to diarrheal diseases with 206,133.79 (95% UI: 145,965.76– 292,139.86)
DALYs in 1990. However, in 2017, the most vulnerable group was the 1-4-year-olds
with 83,578.53 (95% UI: 53,231.443 – 124,013.45) DALYs. There doesn’t seem to be
a clear explanation for this shift.

On a global scale, infants, 28-364 days old were again the most vulnerable to diarrheal
diseases in 1990 and 2017 at 72,710,222.04 (95% UI: 63,366,316.83 –
82,038,201.88) DALYS and 25,200,783.96 (95% UI: 22,457,911.40 – 28,191,106.60)
for males and females.

In Figure 13, we compared 1990 DALYs to 2017 DALYs by age and by sex. Males
had slightly higher DALYs at 37,050,104.87 (95% UI: 29,642,441.65 – 43,624,887.49)
versus 35,660,117.17 (95% UI: 30,938,542.58 – 40,580,555.92) DALYs for females
28-364 days old.

The same trend is observed in 2017, with males having higher DALYs at
13,552,012.55 (95% UI: 11,551,907.13 – 15,808,093.94) compared to females at
11,648,771.41 (95% UI:10,140,980.26 – 13,443,270.64) DALYs.
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Figure 13: Global DALY Counts by Gender and Age (1990-2017).

69

Male

Relationship Between DALY Rates and SDI
By comparing WB High-income to WB Low-income countries throughout this paper,
we aimed to report on the impact of economic and infrastructure development on
health, in this case as it relates to diarrheal diseases. In all areas of our analysis, WB
High-income citizens fared better than citizens of WB Low-income regions. The SDI
metric measures a region’s socio-demographic development considering data about
the education levels, average income per person, and total fertility rate (TFR) then
reports a value between zero and one, one indicating the greatest development.

The global SDI is a good summary of the socio-economic progress that has been
made globally. In Figure 13, we plotted global DALY rates from 1990 to 2017 against
average WB High-income, WB Low-income, and Global SDI values for each year,
respectively. We observe a cubic polynomial relationship in the WB high-Income
regions, where SDI values are highest and DALYs lowest. Looking at the curve of the
graph, it imitates the trend we saw in Figure 3 where, there was at first a decrease in
the number of DALYs from 1990 to 1998, where the number of DALYs started to
increase for unclear reasons. In contrast, DALY rates in WB Low-income regions and
Globally have a linear relationship with SDI value. As the SDI increases, DALY rates
per 100,000 decrease over time. Looking at the data, it seems that SDI has a great
impact on DALY rates in Low-income countries with Low-income, but that impact is
lost as the SDI increases.
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IV.

Discussion

In this study, we have discerned the impact of diarrheal diseases by examining DALYs,
a measure that reports the number of lost “healthy” years in a population due to a
specific illness. Overall, our analyses show that global diarrheal diseases DALYs have
decreased. Surprisingly, the decline in DALYs was more dramatic for WB Low-income
regions than for WB High-income regions. While DALYs have decreased, incidence
and prevalence have increased by 52.16% and 47.22%, respectively. Regardless of
WB income regions infants 28-364 days were the most vulnerable to diarrheal
diseases. However, there were unexplained peaks of DALYs for the 20-24 and 60-64
age groups. Since 1990, global diarrheal disease DALYs did not differ markedly
between the sexes. We also observed that the rate of diarrheal diseases highly
correlates to socio-demographic index (R² = 0.9937).

We hypothesized that socio-economic status would have a great impact on the overall
health of a population. For that reason, for most of our analyses, we compared the
data between WB High-income countries and WB Low-income countries, after which
we refined our analyses by age and sex. Although mortality rates have declined, these
data show that diarrheal diseases still affect the quality of life of individuals of all ages,
particularly in WB Low-income regions.

In each year since 1990, DALYs for children 28 to 364 days old were the highest
suggesting that this group continues to be the most vulnerable population regardless
of income region. This is also the group for which mortality is highest (14,32), albeit
this metric has declined from 1990 to 2017 (26). This progress in lowering childhood
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mortality is due to several factors including, female education, which has contributed
to improvements in hygiene and sanitation, wider access to better nutrition, increased
breastfeeding, better supplemental feeding, increased use of oral rehydration therapy
(ORT), and measles immunization (40-42). Several studies have shown the impact
that improvements in children nutrition, access to clean safe water and food, as well
as treatment with rehydration therapy have had on reducing the number of diarrheal
diseases related deaths (14,43).

The significant lag of WB Low-income countries compared to WB High-income
countries in yearly DALY rates observed is alarming, particularly for children under
five. Children who experience multiple bouts of diarrheal disease start at an unequal
footing for a quality life later in life, experience less economic growth as adults (44).
The impact of diarrheal diseases on crucial early cognitive development is well
documented. Children who experienced multiple episodes of diarrheal have lower
scores on the Test of Non-Verbal Intelligence-III and the Wechsler Intelligence Scale
for Children, they also suffer visual-motor coordination impairment, slowed auditory
short-term memory and information processing; and are at a higher risk of malnutrition,
diabetes, and cardiovascular disease in adulthood (15,17,19,45,46). Further, diarrheal
diseases have been linked to growth stunting in children. An analysis of nine separate
studies done over a 20-year time period and in five countries showed that stunting was
directly linked to multiple episodes of diarrhea in infants under two years of age, where
the proportion of stunting attributed to five or more episodes of diarrheal before 24
months increased the probability of stunting by 25% (95% CI 8-38%). The same study
also showed that the likelihood of stunting was increased by 18% (95% CI 1-31%) for
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children who suffered from diarrheal diseases at least 2% of the time before 24 months
of life (47).

It is well known that diarrheal diseases disproportionately affect populations in poverty
and conflict-ridden countries. It is therefore unsurprising that we found a strong
negative correlation between SDI and diarrheal diseases’ DALYs globally (R² =
0.9937). Data shows that caregiver knowledge as it relates to Water, Sanitation, and
Hygiene (WASH) is an important factor in preventing diarrhea (48-50). As the SDI
value for a country goes up so does the education level of its population, notably its
women. Since women are the primary caregivers in most cultures, their education on
WASH leads to a significant decrease in diarrheal rates among children (48-50).
However, we saw that SDI’s impact on diarrheal diseases weakens as a region’s SDI
value increases.

Our analysis has shown a small spike in diarrheal diseases DALYs in the elderly at
60-64 years in WB Low-income countries and 80-84 years in WB High-income
countries. Previous studies have reported that diarrhea impacts at least 9% of the
elderly population at any given time. This has a significant negative impact on their
quality of life, increasing their hospital visits and hospitalization (51). Other studies
have reported that diarrheal diseases in the elderly population are a significant cause
of fecal incontinence (52), morbidity (53,54), and mortality (35). Long-term care facility
stay for the elderly was cited as a risk factor for diarrheal diseases (35). Consumption
of multiple medications was also reported as a risk factor for diarrheal disease, with a
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11.0% increase of diarrheal disease prevalence in patients who were taking 3–5 drugs,
and an 11.7% increase in patients taking 6 or more drugs at once (55).

To our knowledge, our study is the first to make a longitudinal analysis of DALYs
associated with diarrheal diseases. Our data show that diarrheal disease associated
DALYs have not markedly changed (WB High-income regions). There was a slight
decrease until around the year 2000, where DALY rates started to slowly increase in
high income countries for unclear reasons. In contrast, WB Low-income regions
experienced a more dramatic drop in DALY rates from 1990 to 2017 although yearly
DALY counts are still noticeably higher than in WB High-income regions. Overall,
diarrheal diseases DALYs have been declining at a slower pace than that for mortality
(26). This indicates that increased intervention is necessary.
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APPENDIX 1: Summary of DALY Counts, Incidence Counts, Prevalence Counts, DALY Rates
Due to Diarrheal Diseases and Global SDI Values (1990-2017).
Year

DALYS(COUNT)

Yearly
%
change
(19902017)

Incidence
(COUNT)

Incidence
Yearly %
change
(19902017)

Prevalence
(COUNT)

Prevalence
Yearly %
change
(1990-2017)

DALYS
Rate
per
100,000

1990

178669278.768251
(154235572.289659203868117.467447)
176211231.975992
(152417710.105072200713544.810044)
171391104.702396
(148048548.745833 195423133.839874)
167336245.367074
(144492458.9642 190729559.825914)
163531094.361715
(141140449.762872185920622.828311)
159309627.496529
(137848574.959731181558619.24657)
153873908.661665
(133776006.168749174777925.406401)
145736711.34143
(127033666.155559166849183.410077)
141526595.809072
(123282039.652002161962088.413046)

-1.38%

4135836824.13
(3811339413.894500759366.83)
4178680590.28
(3862369247.754546537194)
4226896542.33
(3911282047.24 4594888290.47)
4278217512.01
(3963190862.664641663372.13)
4335761075.1
(4021226056.654701326266.54)
4402215884.49
(4085555694.084772086653.91
4484297876.71
(4164814142.094861829301.19)
4692265083.71
(4359523454.045081709755.37)
4795836579.09
(4454579472.375200096430.8)

1.03%

63492658.0347
(59217728.401368111097.4995)
63879563.7307
(59687506.055368353071.6295)
64354761.6535
(60216614.283368748674.8797)
64893253.9959
(60866563.342769276193.9801)
65553334.1273
(61573352.454269964587.0143)
66386638.7427
(62355381.315370879899.7971)
67510156.653
(63422181.519272023108.5209)
70525663.0511
(66426872.409775016339.162)
72025514.4601
(67790211.667276472410.1727)

0.61%

1017.22
18

0.74%

1991
1992
1993
1994
1995
1996
1998
1999

-2.74%
-2.37%
-2.27%
-2.58%
-3.41%
-2.93%
-2.89%
-2.86%

1.14%
1.20%
1.33%
1.51%
1.83%
2.19%
2.16%
1.82%
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Rate per
100,000
Yearly %
change
(1990-2017)
-5.48%

Global
SDI
value

964.375
95

-5.58%

0.53

0.83%

913.410
15

-5.66%

0.53

1.01%

864.453
62

-5.72%

0.54

1.26%

817.651
78

-5.77%

0.54

1.66%

773.044
05

-5.80%

0.55

2.10%

730.643
28

0.00%

0.55

2.08%

690.209
62

-5.95%

0.56

1.69%

651.443
02

-6.00%

0.57

0.52

Year

DALYS(COUNT)

Yearly
%
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Incidence
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Yearly %
change
1990-2017

Prevalence
(COUNT)
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Yearly %
change
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Rate
per
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137477671.468813
(119619790.521677156919816.875706)
132617150.351318
(115367283.211441151733021.850802)
127817914.757423
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(108332371.69601142005129.481731)
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-3.54%
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4943837569.91
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(4629036494.455384716718.55)
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1.19%
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0.26%

107018962.602547
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-4.95%
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2.02%

76789507.0786
(72456555.235881053303.3758)

2001
2002
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2005
2007
2008
2009

2010

-3.62%
-3.55%
-2.85%
-2.49%
-1.64%
-1.81%
-1.23%
-1.66%

0.61%
0.30%
0.25%
0.54%
0.48%
0.18%
0.59%
1.36%
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Rate per
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change
1990-2017
-6.03%

Global
SDI
value

579.637
5

-6.03%

0.58

-0.09%

546.669
54

-6.00%

0.58

-0.10%

515.725
85

-5.96%

0.59

0.33%

486.725
57

-5.90%

0.59

0.46%

459.613
66

-5.94%

0.6

0.38%

409.127
49

-6.11%

0.61

0.78%

385.583
27

-6.15%

0.61

1.45%

363.240
42

-6.17%

0.62

2.02%

342.134
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-6.15%

0.62
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DALYS(COUNT)
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%
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Incidence
(COUNT)

Incidence
Yearly %
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1990-2017

Prevalence
(COUNT)

Prevalence
Yearly %
change
1990-2017

DALYS
Rate
per
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2011

101725967.347824
(89644459.9831456119068365.99207)
96617580.817008
(85160652.2047593113591584.175086)
91843279.9738443
(80612660.6996005108043934.094889)
87650670.122366
(76585397.9347087103537964.791569)
83908966.8746052
(72856397.208552199796525.7447586)
81339102.2962044
(70651187.06081997118555.3102732)
81039363.8553969
(70120051.790449597233423.453799)
Overall % change
1990- 2017

-5.02%

5275902290.88
(4920054852.455665447574.68)
5400283887.57
(5025690557.655801308983.15)
5543032980.65
(5152024164.315964838486.52)
5700740396.17
(5288676893.476146170370.65)
5870845742.81
(5439192527.836344038139.4)
6069024218.27
(5610378301.886570441210)
6292936671.74
(5808374688.146816675433.15)

2.30%

78374946.7055
(73913067.414982791160.1963)
80228490.5323
(75541509.560184874468.7924)
82356346.493
(77356532.758587174559.0467)
84706121.3446
(79257785.589189847391.0056)
87232204.1209
(81513437.236492749672.126)
90165742.5137
(84064543.769196111684.5052)
93472768.3654
(86857153.6399961050.1615)

2.31%

322.318
7

2.58%

2012
2013
2014
2015
2016
2017

-4.94%
-4.56%
-4.27%
-3.06%
-0.37%

54.64%

2.58%
2.77%
2.90%
3.27%
3.56%

52.16%
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DALYS
Rate per
100,000
Yearly %
change
1990-2017
-6.03%

Global
SDI
value

303.982
32

-5.70%

0.63

2.77%

287.579
91

-5.48%

0.63

2.90%

272.629
72

-5.34%

0.64

3.25%

258.801
48

0.00%

0.64

3.54%

258.801
48

-5.20%

0.65

246.010
81
47.22%

0.62

0.65
75.82%

